Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

被引：7

作者：

Locke, Frederick Lundry

Ghobadi, Armin

Jacobson, Caron A.

Jacobsen, Eric D.

Miklos, David Bernard

Lekakis, Lazaros J.

Braunschweig, Ira

Oluwole, Olalekan O.

Lin, Yi

Siddiqi, Tanya

Deol, Abhinav

Reagan, Patrick Michael

Farooq, Umar

Bot, Adrian

Jiang, Yizhou

Rossi, John M.

Xue, Allen

Go, William Y.

Neelapu, Sattva Swarup

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Washington Univ, Sch Med, St Louis, MO 14263 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[5] Univ Miami Hlth Syst, Sylvester Comprehens Care Ctr, Miami, FL USA

[6] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[8] Mayo Clin, Rochester, MN USA

[9] City Hope Natl Med, Duarte, CA USA

[10] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA

[11] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[12] Univ Iowa, Iowa City, IA USA

[13] Kite, Santa Monica, CA USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.3003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3003

引用

页数：2

共 50 条

[31] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Oluwole, Olalekan O.
Forcade, Edouard
Munoz, Javier
de Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron A.
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Zheng, Yan
Vardhanabhuti, Saran
Nater, Jenny
Shen, Rhine R.
Miao, Harry
Kim, Jenny
van Meerten, Tom
BLOOD, 2022, 140 : 10399 - 10401
[32] Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)
Jacobson, Caron A.
Westin, Jason R.
Miklos, David B.
Herrera, Alex F.
Lee, Jennifer
Seng, Judy
Rossi, John M.
Sun, Jennifer
Dong, Jinghui
Roberts, Zachary J.
Vezan, Remus
Avanzi, Mauro P.
Locke, Frederick L.
CANCER RESEARCH, 2020, 80 (16)
[33] Interim Analysis of ZUMA-5: a Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Jacobson, Caron
Chavez, Julio
Sehgal, Alison
William, Basem
Munoz, Javier
Salles, Gilles
Casulo, Carla
Munshi, Pashna
Maloney, David
de Vos, Sven
Reshef, Ran
Leslie, Lori
Yakoub-Agha, Ibrahim
Oluwole, Olalekan
Fung, Henry Chi Hang
Plaks, Vicki
Yang, Yin
Lee, Jennifer
Avanzi, Mauro
Neelapu, Sattva
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S20 - S21
[34] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma
Topp, Max
Van Meerten, Tom
Houot, Roch
Minnema, Monique C.
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin
Avivi, Irit
Kuruvilla, John
Duhrsen, Ulrich
Chu, Rachel
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose'
BLOOD, 2019, 134
[35] ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL).
Neelapu, Sattva Swarup
Chavez, Julio C.
Lin, Yi
Munoz, Javier
Ujjani, Chaitra Shankar
Riedell, Peter
De Vos, Sven
Oluwole, Olalekan O.
Kekre, Natasha
Yang, Yin
Goyal, Lovely
Backhouse, Kate
Milletti, Francesca
Kawashima, Jun
Herrera, Alex Francisco
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[36] A standardized comparison of outcomes in patients (pts) with refractory, aggressive non-hodgkin Lymphoma (rNHL) from the SCHOLAR-1 analysis and the ZUMA-1 study of axicabtagene ciloleucel (axi-cel)
Neelapu, S. S.
Locke, F. L.
Bartlett, N. L.
Lekakis, L. J.
Reagan, P. M.
Miklos, D.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O.
Siddiqi, T.
Lin, Y.
Crump, M.
Kuruvilla, J.
Van den Neste, E.
Link, B. K.
Farooq, U.
Navale, L.
Go, W. Y.
Wiezorek, J.
Gisselbrecht, C.
ANNALS OF ONCOLOGY, 2017, 28
[37] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
Jacobson, Caron A.
Locke, Frederick L.
Miklos, David B.
Herrera, Alex F.
Westin, Jason R.
Lee, Jennifer
Rossi, John M.
Zheng, Lianqing
Avanzi, Mauro P.
Roberts, Zachary J.
Sun, Jennifer
BLOOD, 2018, 132
[38] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
Jacobson, Caron A.
Locke, Frederick L.
Miklos, David B.
Herrera, Alex F.
Westin, Jason R.
Lee, Jennifer
Rossi, John M.
Sun, Jennifer
Zheng, Lianqing
Avanzi, Mauro P.
Roberts, Zachary J.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
[39] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Topp, Max S.
van Meerten, Tom
Hout, Roch
Minnema, Monique C.
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin W.
Avivi, Irit
Kuruvilla, John
Duehrsen, Ulrich
Chu, Rong
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
MOLECULAR THERAPY, 2020, 28 (04) : 577 - 577
[40] Phase 1 Results From ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination With Atezolizumab for the Treatment of Patients With Refractory Diffuse Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 14 - 15

← 1 2 3 4 5 →